This week in pharma… 23rd September

In this week’s news, MedPharm announced that it will support Swiss Biotech company Mosanna Therapeutics, Nuvera Life Science Consulting to announce its second annual awards for the three pharmaceutical companies designated as “best-in-class”, and more.

MedPharm, a global provider of contract topical and transdermal formulation development and manufacturing services, is pleased to announce that it will support Swiss Biotech company, Mosanna Therapeutics, in the development of a nasal spray (MOS-118) aimed at treating Metabolic Obstructive Sleep Apnea (MOSA).

Nuvera Life Science Consulting, part of Ashfield Engage, is pleased to announce its second annual awards for the three pharmaceutical companies designated as “best-in-class” by physicians and support staff: AbbVie in immunology, AstraZeneca in oncology, and Biogen in neurology.

‘Truly remarkable’ drug helps motor neurone disease’ – Scientists say they have slowed and even reversed some of the devastating and relentless decline caused by motor-neurone disease (MND). The treatment works in only 2% of patients but has been described as “truly remarkable” and a “real moment of hope” for the whole disease. 

Merck, known as MSD outside the United States and Canada, has joined Accumulus Synergy – a non-profit organization working to develop an information and data exchange platform aimed at transforming how life science innovators and health authorities worldwide interact. 

Roquette Acquires India-Based Crest Cellulose. Following its purchase of a majority share in the company in 2018, this latest move allows Roquette to continue realizing its strong growth ambitions and meet the rising global demand for high-quality plant-based excipients.

“At Roquette, we believe true innovation can only be achieved in an environment where ingredient safety is completely assured,” comments Paul Smaltz, Vice President, Roquette Pharma Solutions.